Holzkirchen, September 3, 2015 – Sandoz, a Novartis company, announced today that ZarxioTM (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US.
“As the pioneer and global leader in biosimilars, Sandoz has maintained a commitment to bringing high-quality biosimilar medicines to patients and healthcare professionals around the world,” said Richard Francis, Global Head, Sandoz. “With the launch of Zarxio, we look forward to increasing …